Background: Pioglitazone has shown an inhibitory effect on the growth of cell lines derived from human salivary gland and human oral squamous cell carcinoma. However, whether this effect can be applied to patients with type 2 diabetes mellitus who use pioglitazone for glycemic control remains unanswered.
Methods: The reimbursement records of all Taiwanese diabetic patients under treatment with oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance database. The entry date was set at 1 January 2006 and a total of 1,093,391 patients with type 2 diabetes were followed up for oral cancer incidence till the end of 2009. Incidences for ever-users, never-users and subgroups of pioglitazone dose-responsive exposure (using the parameters of time since starting pioglitazone, duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression.
Results: There were 58,238 ever-users and 1,035,153 never-users, with respective numbers of incident oral cancer of 201 (0.35%) and 4168 (0.40%), and respective incidences of 94.26 and 114.24 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) did show a significantly lower risk in unadjusted [0.832 (0.722-0.958)] and age-sex-adjusted [0.866 (0.752-0.998)] models. However, the multivariable-adjusted hazard ratio (95% confidence interval) was not significant: 0.992 (0.857-1.148). Although significant P-trends for the dose-response parameters could be observed in some of the unadjusted and age-sex-adjusted models, none was significant in the multivariable-adjusted models.
Conclusions: Pioglitazone has a null association with oral cancer after adjustment for potential confounders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oraloncology.2013.10.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Everyday activity strategies perceived by people with advanced cancer: a qualitative explorative study.
BMC Palliat Care
January 2025
DEFACTUM, Central Region Denmark, Aarhus, Denmark.
Background: Despite growing research on the daily life of people with advanced cancer, more specific knowledge is needed about the specific strategies these people use to manage everyday activities.
Purpose: This study explores how people with advanced cancer manage their everyday activities and describe their specific strategies.
Methods: The qualitative study was designed with an explorative approach.
Artificial intelligence for image recognition in diagnosing oral and oropharyngeal cancer and leukoplakia.
Sci Rep
January 2025
Department of Otolaryngology Head and Neck Surgery, Technical University Munich, Munich, Germany.
Visual diagnosis is one of the key features of squamous cell carcinoma of the oral cavity (OSCC) and oropharynx (OPSCC), both subsets of head and neck squamous cell carcinoma (HNSCC) with a heterogeneous clinical appearance. Advancements in artificial intelligence led to Image recognition being introduced recently into large language models (LLMs) such as ChatGPT 4.0.
View Article and Find Full Text PDFRelationship between muscular mass, inflammatory status, tumor metabolic activity and oral intake in head and neck cancer at the outset of management.
Clin Nutr ESPEN
January 2025
Service d'orl et chirurgie cervico-faciale, CHU de Clermont-Ferrand, 58 rue Montalembert, 63000 Clermont-Ferrand, France; Unité de Nutrition Humaine (UNH), Université Clermont Auvergne, INRAE, CRNH Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France. Electronic address:
Background And Aims: Patients with head and neck cancer (HNC) are often malnourished with a low muscular mass at the outset of management. This is thought to be mainly due to poor nutritional intake. The aim of this study was to assess the correlation between tumor metabolic activity, inflammatory status and body composition in HNC patients.
View Article and Find Full Text PDFInvestigation of aerosol jet printing for the preparation of solid dosage forms.
Int J Pharm
January 2025
EPSRC CMAC Future Manufacturing Research Hub, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 99 George Street, Glasgow G1 1RD UK; The Cancer Research UK Formulation Unit, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral St, Glasgow G4 0RE UK.
Oral drug delivery remains the preferred method of drug administration but due to poor solubility many active pharmaceutical ingredients (APIs) are ill suited to this. A number of methods to improve solubility of poorly soluble Biopharmaceutical Classification System (BCS) Class II drugs already exist but there is a lack of scalable, flexible methods. As such the current study applies the innovative technique of aerosol jet printing to increase the dissolution capabilities of a Class II drug in a manner which permits flexibility to allow dosage form tailoring.
View Article and Find Full Text PDFIs postoperative adjuvant therapy necessary for pT3N0 oral cavity squamous cell carcinoma?
Oral Oncol
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University Taoyuan Taiwan Republic of China. Electronic address:
Background: The current NCCN guidelines advocate for the use of adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) in pT3N0 oral cavity squamous cell carcinoma (OCSCC). Here, we sought to evaluate whether postoperative RT/CRT may confer a survival advantage in pT3N0 patients who lack adverse pathological features.
Methods: A dataset of 852 pT3N0 OCSCC patients treated between 2018 and 2021 was analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!